On 16–17 March 2026, ONCOVALUE partners gathered in Porto, Portugal, for a two-day consortium meeting hosted at the Escola Portuguesa de Oncologia do Porto (EPOP). The meeting brought together project partners to review progress, exchange insights, and align on the next steps towards delivering value-based oncology care across Europe.

The first day focused on scientific and technical advancements across key areas of the project. Discussions covered the latest results from the Delphi study, developments in ethical, legal, and social implications (ELSI), and progress within the triple-negative breast cancer (TNBC) use case. Participants also explored how to generate reliable evidence from real-world data in the context of the emerging European Health Data Space (EHDS), highlighting both opportunities and challenges for data-driven oncology.

A dedicated technical session showcased cutting-edge work, including AI-driven imaging analysis, the transformation of unstructured clinical text into structured outcomes using natural language processing, and the application of large language models to assess cancer progression from radiology reports. These discussions underscored the project’s strong focus on leveraging advanced analytics and artificial intelligence to improve clinical decision-making.

The second day centred on project coordination and future impact. Partners reviewed overall progress and discussed the path towards project completion, with particular attention to sustainability and exploitation strategies. The meeting concluded with a General Assembly, reinforcing collaboration and alignment across the consortium.

The Porto meeting marked another important milestone for ONCOVALUE, strengthening collaboration among partners and reinforcing the project’s commitment to delivering innovative, data-driven solutions for more effective and sustainable cancer care in Europe.